News
INSM
25.27
+4.81%
1.16
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Spero Therapeutics, Inc. Is on the verge of generating landmark data with multi-bagger potential. The company's three pipeline assets are progressing step by step. I believe Spero is fundamentally undervalued based on the GSK aka GlaxoSmithKline (GSK) deal alone.
Seeking Alpha · 1d ago
INSMED INC <INSM.O>: TRUIST SECURITIES INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $48
Reuters · 1d ago
Insmed Initiated at Buy by Truist Securities
Dow Jones · 1d ago
Insmed Price Target Announced at $48.00/Share by Truist Securities
Dow Jones · 1d ago
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
TipRanks · 1d ago
Truist Securities Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $48
Benzinga · 1d ago
Weekly Report: what happened at INSM last week (0415-0419)?
Weekly Report · 2d ago
Relative Strength Alert For Insmed
NASDAQ · 5d ago
Weekly Report: what happened at INSM last week (0408-0412)?
Weekly Report · 04/15 09:14
Insmed Is Maintained at Overweight by Barclays
Dow Jones · 04/11 13:40
Barclays Maintains Overweight on Insmed, Raises Price Target to $40
Benzinga · 04/11 13:29
INSMED INC <INSM.O>: BARCLAYS RAISES TARGET PRICE TO $40 FROM $37
Reuters · 04/11 11:11
ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary
Seeking Alpha · 04/09 15:00
Weekly Report: what happened at INSM last week (0401-0405)?
Weekly Report · 04/08 09:15
Insmed Price Target Maintained With a $55.00/Share by Wells Fargo
Dow Jones · 04/01 16:11
Insmed Is Maintained at Overweight by Wells Fargo
Dow Jones · 04/01 16:11
Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
Benzinga · 04/01 16:01
Wells Fargo's high-conviction tactical longs and shorts for Q2
Wells Fargo's high-conviction tactical longs and shorts for Q2 include two Magnificent 7 names. The list includes 10 long (or Overweight) trades and 4 short (or Underweight) ideas. The Wells Fargo equity team identified 14 high- Conviction, catalyst-driven stock opportunities for the second quarter.
Seeking Alpha · 04/01 12:53
Insmed's (NASDAQ:INSM) investors will be pleased with their favorable 56% return over the last year
Insmed Incorporated's share price is up 56% in the last year, besting the market return of 26%. The company's revenue grew by 24% over the last 12 months. The share price of Insmed is 23% lower than it was three years ago. Insmed doesn't make a profit, but shareholders have pushed the share price up by 56%. You can boost your returns by picking above-average stocks.
Simply Wall St · 04/01 11:13
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)
TipRanks · 04/01 10:03
More
Webull provides a variety of real-time INSM stock news. You can receive the latest news about Insmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).